Summary: Lipoprotein(a) is a cholesterol-rich plasma lipoprotein consisting of LDL and apolipoprotein (a). Apolipoprotein(a) shows structural similarity with plasminogen and thus may interfere with thrombogenesis. Lipoprotein(a) has been shown to be a strong independent risk factor for coronary heart disease.
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We therefore looked at changes in plasma lipoproteins (low density lipoprotein-cholesterol, total high density lipoprotein-cholesterol and subfractions, apolipoprotein A-I, apolipoprotein A-II, apolipoprotein B) and lipoprotein(a) in a group of 28 post menopausal women treated for 6 months with Tibolone (Livial®; Organon International) and in a control group of untreated volunteers. Tibolone is a synthetic steroid, (7a,17a)-17-hydroxy-7-methyl-19-nor-pregn-5(10)-en-20-yn-3-one, structurally related to the progestogens, norethynodrel and norethisterone ( fig. 1) . It shows weak progestogenic, oestrogenic and androgenic actions in animal tests (8) . Tibolone has been shown to be effective in the relief of climacteric symptoms (9 -11) and in preventing post menopausal bone loss (12) . Tibolone is also effective in the treatment of established postmenopausal osteoporosis (13) . A further advantage of Tibolone is the absence of endometrial stimulation (14, 15) . Thus, in non-hysterectomized women no withdrawal bleeding occurs, an otherwise leading cause for discontinuation of hormone replacement therapy.
Patients and Methods

Patients
In 28 apparently healthy, early post menopausal women, serum lipids, lipoprotein(a), low density lipoprotein-and high density lipoprotein-cholesterol, and the apolipoproteins A-I, A-II and Β were measured before and after 6 months of hormone substitution with Tibolone 2.5 mg daily. The results were compared with a control group of 28 age-matched postmenopausal volunteers not wishing to receive hormonal substitution therapy. All women participating in the study were recruited among patients consulting our endocrinological outpatient consultation for climacteric symptoms. None of the women had taken oestrogen gestagen medication during at least 2 months prior to the first examination, and none took lipid-lowering or any other type of drug. They were advised not to change their diet and smoking habits.
The major characteristics of the study population are given in table 1. The two groups did not differ statistically. Menopause was ascertained by serum follitropin values above 30 U/l.
All patients gave their informed consent to participation in the study. The study protocol was approved by the ethical committee of the women's hospital of the University of Berne. 
Methods
Fasting blood samples were obtained from all subjects before enrolment in the study and after 6 months. All sera were stored at -20 °C until analysed. Total cholesterol and triacylglycerols were measured by enzymatic methods (Boehringer Mannheim), high density lipoprotein-cholesterol was determined after precipitation with phosphotungstate Mg ?+ (Boehringer Mannheim), and low density lipoprotein-cholesterol was measured after precipitation with an amphiphilic polymer (Bio Merieux, Lyon) in the washed and re-dissolved precipitate. The high density Hpoprotein 2 /high density Iipoprotein 3 (HDL 2 /HDL 3 )-ratio was measured by precipitation with polyethylene glycol according to Kostner (16) . Apolipoproteins A-I, A-II and B were measured by immunonephelometry on a Behring Nephelometer Analyser (Behririgwerke Marburg). The between-run coefficient of variation for apolipoprotein-A-I was 4.6% at 1.7 g/1 and the within-run coefficient of variation was 1.8%. The between-run coefficient of variation for apolipoprotein B was 3.3% at 1.22 g/1 and the within-run coefficient of variation was 1.9%. Apolipoprotein values were standardised with reference material from Behring-Werke which is proposed as the WHO standard.
Lipoprotein(a) was measured by immunoradiometric assay (Pharmacia Uppsala). This method was shown not to be affected by storage of samples in the frozen state. The betweenrun coefficient of variation for lipoprotein(a) was 9.7% at 93 mg/1.
Statistical analysis
The comparison of initial values, treatment differences within groups after 6 months and comparison of treatment changes between groups were statistically analysed with Student's test. For lipoprotein(a), which is known for its skewed distribution, logarithmic transformation was performed before testing. Testing was performed two-sided. All p-values below 0.05 were considered to be significant.
JResults
Initial lipid and lipoprotein values did not differ between the two groups of volunteers (tab. 2). Lipoprotein(a) concentrations showed the typical skewed var- Twenty-four of the 28 lipoprotein(a) values showed a decrease after treatment with Tibolone, the largest decreases occurring in the 7 patients with the highest pre-treatment values.
The mean change of lipoprotein(a) as a percentage of the initial value in the 7 patients with highest initial values (upper quartile) was 0.7% in the controls and -42.9% in the treated group, this difference between the two groups being highly significant (p < 0.004).
The individual changes in lipoprotein(a) levels are illustrated in figure 2. 
Discussion
It is well established that oestrogens and progestins have different effects on lipoproteins. Oestrogens are associated with a decrease in the atherogenic low density lipoprotein fraction and with an increase in the concentration of high density lipoprotein, shown to be negatively associated with coronary heart disease. Tibolone, which was used in the present study, is a synthetic steroid with oestrogenic, progestogenic and weak androgenic activity. We confirmed an already known significant decrease in high density lipoprotein-cholesterol (17) (17) . However, in view of the important decrease of total high density lipoprotein, an increase of the coronary risk has to be postulated.
On the other hand, recent data from experiments in Cynomolgus monkeys showed that the extent of coronary atherosclerosis was lessened by oestrogen gestagen combination, despite the fact that serum concentrations of high density lipoprotein-cholesterol were lowered (19) .
In our treatment group no significant alteration was observed for total cholesterol, triacylclycerols and low density lipoprotein-cholesterol, while apolipoprotein B showed a highly significant increase of 17.1%. Elevated serum concentrations of apolipoprotein B are significantly correlated with a higher risk for cardiovascular disease in women (20) . In both groups we found no significant influence on triacylglycerol serum concentrations, but there was a slight decrease of 4% (Tibolone) and 6% (controls), compared with the initial values. These results are not in accord with earlier findings (17, 21) of a significant decrease (20%) of triacylglycerol after Tibolone treatment. Elevated concentrations of triacylglycerols are considered to be associated with a higher risk for cardiovascular disease (22, 23) .
The main focus of our study, however, was the response of lipoprotein(a), (an independent risk factor for coronary heart disease) to Tibolone treatment. It is difficult to influence the le f vel of lipoprotein(a). Conventional hormone replacement therapy with oral oestrogens only marginally decreased serum concentrations of lipoprotein(a), probably due to a minor influence on its hepatic synthesis (24) . A decrease of lipoprotein(a) in the order of 50%, due to combined postmenopausal hormone replacement therapy with 1.25 mg conjugated oestrogens daily plus 10mg medroxyprogesterone acetate for 10 days a month as described by Soma et al. (25) Statistical analysis of plasma lipoprotein(a) levels is difficult because of their extremely skewed distribution in the white race. In a non-selected population, values above a cut-off-point of 300 mg/1, which are thought to be associated with increased risk for coronary heart disease, are observed in about 20% of healthy volunteers (W. Riesen: MONICA-Switzerland, unpublished data). In our study group of 56 post menopausal women, lipoprotein(a) concentrations above 300 mg/1 were observed in 21%.
In the group of 28 women treated with Tibolone there was a highly significant decrease in» the concentrations of lipoprotein(a). The mean decrease was 26.1%, while in the untreated group a mean increase of 1.7% was observed. Compared with lipid lowering drug treatment, where effects in the order of a 30% decrease are only seen with very potent lipid regulating agents, the change of lipoprotein(a) with Tibolone treatment is certainly remarkable. These findings are consistent with the results of a pilot study by Parish et al. (35) who demonstrated a significant decrease of the median serum lipoprotein(a) values of 47% in 9 women treated with 10 mg norethisterone daily for 2 months. Tibolone shows a close structural similarity to norethisterone. These data are compatible with an unexpected constellation of a theoretically unfavourable fall of high density lipoprotein and a favourable change of lipoprotein(a) values.
In conclusion, Tibolone is so far the only complete post menopausal hormone replacement therapy that shows a significant decrease of serum concentration of lipoprotein(a) after an oral intake of 2.5 mg daily. Its effort on lipoprotein(a) concentrations, however, might counterbalance, at least to some extent, the adverse effect of Tibolone on other lipoprotein risk factors such as the important decrease of high density lipoprotein-cholesterol and the significant increase in apolipoprotein B. The clinical long-term effect of Tibolone on the risk of coronary heart disease, known to be elevated in unsubstituted post menopausal women, has to be evaluated in prospective long term studies.
